Cannabidiol (CBD), hemp extract, broad-spectrum hemp, full-spectrum hemp, CBG, CBN — the hemp-derived supplement category is commercially enormous and regulatory clarity remains elusive. FDA has not issued final rules on CBD as a dietary supplement ingredient, enforcement has been selective, and state regulatory frameworks vary significantly. Brands operating in this category need to understand the current federal posture, claim rules that apply if the product is treated as a supplement, and where enforcement has historically focused.
The Drug Exclusion Issue
Under 21 U.S.C. 321(ff)(3)(B)(ii), an article cannot be marketed as a dietary supplement if it was first authorized for investigation as a new drug under 21 U.S.C. 355(i) — unless it was first marketed as a food or supplement before that IND authorization.
Epidiolex (CBD) received FDA drug approval in 2018. FDA has consistently taken the position that CBD was the subject of IND investigation before it was widely marketed as a supplement, excluding it from the supplement category. FDA issued a high-profile statement on this position in 2023 and recommended that Congress act to create a lawful pathway for CBD in food and supplements.
As of 2026, no such legislation has passed. FDA enforcement against CBD products has been limited but primarily focused on disease claims. Brands operating in the space should understand that the ingredient itself, not just the claims, carries regulatory exposure.
What Claims Are Permissible (If Treated as a Supplement)
If a brand is selling a hemp-derived product positioned as a supplement, structure/function claims under 21 CFR 101.93(f) that may be permissible include:
"Supports a healthy stress response"
"Promotes a sense of calm"
"Supports healthy sleep"
"Promotes relaxation"
"Supports the endocannabinoid system"
"Helps maintain a balanced mood"
"Supports recovery from exercise"
These claims describe normal physiological states and function support. They are the highest-compliance framing available in this category.
Where CBD Claims Cross the Line
Prohibited disease claims:
"Treats anxiety" — anxiety disorder is a named disease; treatment claims require drug approval
"Reduces seizures" — explicit reference to the indication for which Epidiolex was approved (epilepsy/seizures)
"For PTSD" — named psychiatric condition
"Treats chronic pain" — pain treatment is a drug claim
"Anti-inflammatory" as a treatment descriptor — in disease context (arthritis, IBD), this is a disease claim
"Helps with opioid withdrawal" — implies treatment of a substance use disorder
"For people with autism" — named developmental condition
"Reduces cancer treatment side effects" — disease/treatment claim
"Lowers blood pressure" — disease claim (hypertension)
The anxiety claim is the most common violation
FDA warning letters for CBD products consistently cite anxiety treatment claims — "reduces anxiety," "for anxiety relief," "treats anxiety and stress disorders" — as the highest-frequency prohibited claim type. The combination of drug exclusion issues and anxiety disease claims represents the dual-exposure scenario most likely to trigger enforcement action.
FTC Enforcement in CBD
The FTC has been actively involved in CBD enforcement alongside FDA. Under FTC Act Section 5 (15 U.S.C. 45), CBD brands face the same substantiation requirements as any supplement advertiser — competent and reliable scientific evidence for specific outcome claims. FTC has issued warning letters to CBD brands for claims about pain, anxiety, cancer, and other conditions that lacked adequate substantiation, independent of the FDA drug exclusion issue.
State Law Considerations
Several states have enacted their own hemp/CBD regulations that are distinct from and sometimes stricter than federal requirements. California, New York, and Texas have each issued guidance affecting CBD food and supplement marketing at the state level. A product that navigates federal claim requirements may still face state-level issues depending on distribution.
CBD claims require dual compliance review — ingredient legality and claim language simultaneously
Truli scans CBD and hemp supplement claims against both the 21 CFR 101.93(g) disease claim framework and the ingredient-level exposure from FDA's drug exclusion position — flagging disease claims (anxiety, pain, seizure, psychiatric) that generate the most consistent enforcement attention in this category.
A note from Truli: Truli is not a law firm, and this article does not constitute or contain legal advice or create an attorney-client relationship. When determining your obligations and compliance with respect to relevant laws and regulations, you should consult a licensed attorney.
